bevacizumab,panitumumab
roche,takeda,amgen
['paradigm', 'colorectal', 'beva', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'bevacizumab', 'panitumumab', 'rectal']
panitumumab (pan) plus mfolfox6 versus bevacizumab (bev) plus mfolfox6 as first-line treatment in patients with ras wild-type (wt) metastatic colorectal cancer (mcrc): results from the phase 3 paradigm trial #asco22 
Medicina Interna - Oncología Clínica - Profesor Titular @UPBColombia - Clínica Astorga. #Medellín / #Colombia mlujanonco@gmail.com #OncTwitter #Metaanalysis